If I'm not mistaken, most of the people who have taken positions did so after O'Karma left and the stem cell assets were divested. The jettisoning of the legacy assets were a requirement for me. Therefore I don't think the discussion today has much to do with the past.
Sometimes companies shake off a bad dream and turn things around with a new focus. For years PCYC was basically a joke, appointing people Genta's former CMO onto their board as they chased drugs like Xcytrin.